New Hampshire House Passes Scaled-Back Psilocybin Bill, Rejects Gun Rights Measure
New Hampshire's House recently passed a scaled-back psilocybin bill reflecting evolving psilocybin policy developments. These legislative changes create regulatory uncertainty impacting clinical planning and patient access. Clinicians should monitor…
Lawmakers Debate Regulation of Psychedelic Clinical Trials
Legislative frameworks are shaping the regulation of psychedelic clinical trials, impacting patient access to emerging therapies. As FDA approval processes progress for psilocybin and MDMA, lawmakers debate safety and training protocols. Psychedelic…
Dabney: Yes to magic mushroom therapy in Minnesota, but let’s do it right – Star Tribune
Minnesota is developing a psilocybin therapy regulatory framework to ensure safe and evidence-based access to psychedelic medicine. This framework will influence clinical safety protocols and facilitator training. The psilocybin therapy regulatory…
Governor Signs Bill to Launch Ibogaine Clinical Trials – Magnolia Tribune
Ibogaine clinical trials legislation marks a significant step in addiction treatment research. This bill enables formal studies to evaluate ibogaine's efficacy and safety. It opens regulatory pathways for controlled psychedelic clinical trials.
Dr. Blest-Hopley: Neuroscientist Specializing in Psychedelic & Cannabinoid Research
Psychedelic neuroscience research is advancing our understanding of cannabinoid mechanisms and therapeutic potential. Dr. Blest-Hopley’s work highlights emerging clinical relevance in this field. This research may inform future treatments combining…
Mississippi Governor Vetoes Medical Cannabis Expansion Bills
Mississippi medical cannabis program challenges continue as the governor vetoes bills expanding access. This policy decision impacts patient care and clinical decision-making. Meanwhile, psychedelic research initiatives advance, creating a complex…
Ibogaine Research Pilot Program One Step Closer to Reality After Committee Vote – Denver7
The ibogaine research pilot program in Colorado marks a significant step toward clinical investigation of this psychedelic. This program focuses on addiction treatment research while addressing cardiac safety concerns. The pilot aims to establish…
Cannabis and Psychedelics Among U.S. Young Adults: Use, Messaging Exposure, Perceptions, and Legalization Support.
This study analyzed cannabis psychedelic use young adults in the U.S. focusing on use patterns, messaging exposure, and legalization support. It provides key insights into perceptions among 18-34 year olds. The findings help inform clinical understanding…
The combination of exercise and psychedelics for the treatment of major depressive disorder.
Upwards of 50% of people do not respond to the primary treatment modalities for major depressive disorder (MDD), which has led to increased attention and use of combination exercise psychedelics depression approaches. This commentary explores the…
A New Take on the Antidepressants vs Psychedelics Efficacy Debate – Drug Science
This article explores psychedelic therapies for depression, focusing on their efficacy compared to traditional antidepressants. It highlights the clinical complexity in comparing these treatments for patients with treatment-resistant depression.…